If you run a metabolic or longevity practice in 2025, you've almost certainly had this conversation: a 48-year-old patient walks in with a borderline-low IGF-1, complaints of poor recovery and visceral adiposity, and a printout from the internet asking about "sermorelin stacks." The temptation is to either dismiss the request or reach for recombinant human growth hormone (rhGH). Both are wrong answers. rhGH suppresses endogenous pulsatility and carries a regulatory profile few clinics want to shoulder. Dismissing the patient sends them to the gray market. The clinically defensible middle path — growth hormone secretagogue (GHS) peptides used within physician-supervised research protocols — requires understanding something most practitioners were never taught in medical school: the GH axis is not a volume knob. It is a rhythm.
This piece is a working guide to that rhythm. What follows is not a consumer explainer. It is a mechanism-first review of how GHRH analogs and ghrelin receptor agonists interact with somatotroph biology, what the animal and human data actually show, and how licensed practitioners are structuring research protocols around these compounds.
The Pulsatility Problem: Why rhGH Is a Blunt Instrument
Native growth hormone is secreted in discrete bursts — roughly 6 to 10 pulses per 24 hours in healthy adults, with the largest amplitude pulse occurring during slow-wave sleep. Between pulses, serum GH can be nearly undetectable. This is not a design flaw. Target tissues, particularly the liver and skeletal muscle, are exquisitely tuned to trough-and-peak signaling. Continuous GH exposure — the pharmacokinetic profile of daily rhGH injections — downregulates JAK2/STAT5 signaling, promotes lipolysis-independent insulin resistance, and blunts the very IGF-1 response clinicians are trying to elicit.
This is where secretagogue peptides earn their place. Rather than replacing GH, they coax the somatotroph to release its own stores in patterns that more closely resemble endogenous rhythm. Two receptor families do most of the work: the growth hormone-releasing hormone receptor (GHRH-R) and the growth hormone secretagogue receptor 1a (GHSR-1a), better known as the ghrelin receptor.
What Are GH Secretagogue Peptides?
GHRH Analogs
Sermorelin (GHRH 1-29), tesamorelin, and CJC-1295 are all structural analogs of the endogenous 44-amino-acid hypothalamic peptide GHRH. They bind the GHRH-R on anterior pituitary somatotrophs and trigger cAMP-mediated GH release. Because they act upstream of the pituitary, they preserve hypothalamic negative feedback — meaning somatostatin can still shut the pulse down. This is a critical safety feature. Supraphysiologic GH excursions self-correct.
CJC-1295 differs from sermorelin in two clinically important ways: a tetrasubstituted N-terminus that resists DPP-IV cleavage (extending half-life from ~7 minutes to several hours), and, in the DAC variant, a maleimide linker that binds serum albumin for a half-life measured in days. The DAC variant is powerful but chemically flattens pulsatility — the very feature that made GHRH attractive in the first place. This is why most sophisticated protocols use CJC-1295 without DAC (sometimes labeled Mod GRF 1-29).
Ghrelin Mimetics / GHSR-1a Agonists
Ipamorelin, hexarelin, GHRP-2, GHRP-6, and the orally-active MK-677 (ibutamoren) all bind GHSR-1a. This receptor is the target of endogenous acyl-ghrelin, an octanoylated 28-amino-acid peptide produced by gastric X/A-like cells. GHSR-1a acts through Gq/phospholipase C, producing an intracellular calcium surge that triggers GH exocytosis — a mechanism distinct from, and synergistic with, GHRH signaling.
The synergy matters. When GHRH and a GHSR-1a agonist are administered together, the resulting GH pulse is not additive but multiplicative — often 3 to 5 times the amplitude of either agent alone. This is the mechanistic rationale behind the ubiquitous CJC-1295 + ipamorelin combination that has become the workhorse of research protocols in the field.
The Research: What the Data Actually Shows
GHSR-1a Is Not Optional for Normal Pulsatility
The dependence of the GH axis on ghrelin signaling has been formally established through elegant knockout work. Labarthe and colleagues demonstrated that mice with genetic deletion of GHSR — the ghrelin receptor — show measurable disruption in pulsatile GH secretion patterns, alongside altered growth trajectories and meal-pattern behavior [1]. The takeaway for clinicians is not that ghrelin "causes" GH release; it is that the ghrelin system provides constitutive tone to the somatotroph, and when you remove it, the pulse architecture itself degrades.
Xie and colleagues extended this line of inquiry by knocking out ghrelin-O-acyltransferase (GOAT), the enzyme that octanoylates ghrelin to produce its biologically active acylated form. Even with the ghrelin peptide itself still present, loss of GOAT — and therefore loss of acyl-ghrelin — measurably altered pulsatile GH release in mice [2]. This is direct evidence that it is the acylated ligand, not merely the ghrelin polypeptide, that shapes pulse dynamics. Clinically, this validates why GHSR-1a agonists (which mimic acyl-ghrelin) reliably drive GH pulses in a way that non-acylated ghrelin analogs do not.
The Receptor Beyond GH
GHSR-1a is not a single-purpose receptor. Li and colleagues reviewed its role in energy homeostasis and obesity pathogenesis, describing its expression in hypothalamic arcuate NPY/AgRP neurons, the ventral tegmental area, and peripheral adipose tissue [3]. This is why patients on ghrelin mimetics frequently report appetite changes — MK-677 in particular is notorious for it — and why the metabolic effects of these peptides extend beyond GH-mediated pathways. Practitioners considering GHSR-1a agonists for patients with metabolic syndrome or hyperphagia phenotypes need to weigh this carefully. Ipamorelin, notably, is the most selective GHSR-1a agonist available for research use and has the least appetite-stimulating effect of the class.
Clinical Considerations: Protocol Architecture
Timing Is Everything
Because GHRH analogs work through the pituitary and require both somatostatin withdrawal and somatotroph readiness, timing of administration substantially affects the pulse amplitude generated. The two windows that maximize response are pre-sleep (30 to 60 minutes before bed, aligning with the natural nocturnal pulse) and post-training (capitalizing on exercise-induced somatostatin suppression). Administration within 90 minutes of a carbohydrate-rich meal will attenuate the pulse — insulin and elevated free fatty acids both suppress somatotroph responsiveness.
Frequency and Duration
Research protocols typically employ once- or twice-daily subcutaneous administration cycled over 8 to 12 weeks, followed by a washout period. The rationale for cycling is twofold: preservation of receptor sensitivity (GHSR-1a in particular is prone to homologous desensitization) and periodic reassessment of IGF-1 to ensure the axis is responding within a physiologic band. Sustained IGF-1 elevations above the upper age-adjusted reference range are the primary safety signal to monitor.
Monitoring
At minimum, baseline and 6-week IGF-1, fasting glucose, and HbA1c should be documented. In older patients or those with metabolic comorbidities, consider a fasting insulin and lipid panel. Random GH levels are diagnostically useless given pulsatile secretion; do not order them. Some clinics document body composition via DEXA or BIA at baseline and end-of-cycle, which is both clinically useful and — bluntly — supports patient retention.
Patient Selection
The strongest candidates for GHS research protocols are typically adults age 40 to 65 with age-appropriate IGF-1 decline, adequate sleep architecture, and no active malignancy. Absolute exclusions include active or recent cancer, uncontrolled diabetes, and pregnancy. Relative cautions include severe insulin resistance (GH is counter-regulatory), untreated sleep apnea, and any history of pituitary pathology.
What to Look for in a Source
This is where most clinics get themselves into trouble. The peptide supply chain in the U.S. is bifurcated: on one end, 503A/503B compounding pharmacies operating under state board and FDA oversight; on the other, research chemical suppliers of highly variable quality. For any peptide entering a clinical research protocol, the following documentation is non-negotiable:
Certificate of Analysis (COA) from an independent third-party lab, confirming peptide identity via mass spectrometry and purity via HPLC — you want ≥98% purity as a floor, with the balance characterized (not simply "unknown"). Endotoxin testing (LAL assay) with results below 5 EU/mg for any product intended for parenteral research use. cGMP-manufactured active pharmaceutical ingredient, with documentation of the manufacturing facility and lot-specific testing. Chain-of-custody documentation from synthesis through final vial.
If a supplier cannot produce these documents on request, that is your answer. Cost per vial is a distant second consideration to documentation quality. A clinic's regulatory exposure on a contaminated or mislabeled peptide dwarfs any margin gained from a cheaper source.
Why This Matters for Your Practice
The GH axis conversation is one of the highest-value clinical conversations happening in longevity and metabolic medicine right now, and it is one of the most poorly handled. Patients are arriving informed, motivated, and — critically — willing to invest in properly supervised protocols rather than order unmarked vials from overseas. The clinic that can articulate why pulsatility matters, why CJC-1295/ipamorelin is mechanistically preferable to a rhGH prescription for most adult wellness indications, and why source documentation is a patient-safety issue rather than a bureaucratic hurdle, will win those patients.
There is also a defensive angle. The regulatory environment around peptides in the United States has tightened considerably over the past 24 months, and it will tighten further. Clinics operating with rigorous documentation, appropriate patient selection criteria, and defensible research-protocol framing are the clinics that will still be operating when the dust settles. Clinics running informal "peptide programs" without COAs, informed consent aligned with research use, and monitoring protocols are the ones state boards are already investigating.
The GH axis rewards precision. Practitioners who understand pulsatility — and who can source materials that let them actually deliver it — are practicing at the front edge of the field. Everyone else is either overprescribing rhGH or underserving patients who will find the peptides regardless of whether their physician is involved.
Golden Lotus Labs supplies research-grade GHRH analogs and GHSR-1a agonists exclusively to licensed healthcare providers operating physician-supervised clinical research protocols. All materials ship with third-party COAs, endotoxin data, and lot-specific documentation. For clinics building or refining a GH-axis protocol, our clinical team is available to review sourcing, storage, and monitoring frameworks.